Cambridge Cognition Holdings (COG)

Sector:

Health Care

Index:

FTSE AIM All-Share

 22.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 82.50
  • 52 Week Low: 22.00
  • Currency: UK Pounds
  • Shares Issued: 27.64m
  • Volume: 4,359
  • Market Cap: £6.08m
  • RiskGrade: 356

Cambridge Cognition hoping to ride coat-tails of Biogen Alzheimer's programme

By Josh White

Date: Friday 25 Oct 2019

LONDON (ShareCast) - (Sharecast News) - Cambridge Cognition announced on Friday that, Following a consultation with the US Food and Drug Administration (FDA), Biogen and Eisai have announced plans to pursue regulatory approval for 'aducanumab', which would be the first therapy to tackle clinical decline in early Alzheimer's disease.
The AIM-traded firm said that if successful, it presented an opportunity for it, given its 'CANTAB' assessments are specifically sensitive to the early cognitive decline during Alzheimer's disease.

It said that, despite initial concerns about the efficacy of aducanumab, new analysis of an expanded dataset revealed positive results at higher doses of the drug, with Biogen indicating that they would file for approval in the US early in 2020.

If approved, that would be the first drug to slow the progression of Alzheimer's disease, which Cambridge Cognition described as "a major therapeutic breakthrough", as there had been no new treatments approved since 2003.

The "promising step forward" for Alzheimer's disease raised the urgent challenge of finding and assessing patients who were most likely to benefit from such drugs, with Cambridge Cognition claiming that its 'CANTAB Mobile' product could support clinicians in making that decision.

It explained that CANTAB Mobile delivers an automated memory assessment and depression scale to distinguish older patients who had concerns about their memory from those at increased risk of dementia.

The CE-marked, FDA-cleared and TGA-approved medical device was "poised to help clinicians all over the world" identify patients who were most likely to benefit from disease-modifying treatments, the board added.

"We were delighted to hear the news of Biogen's re-invigorated Alzheimer's programme, as it holds promise for the millions of people worldwide who are affected by the disease," said Cambridge Cognition chief executive officer Matthew Stork.

"We are therefore preparing for the approval of disease modifying treatments so that patients and families can benefit from new therapies as soon as possible. CANTAB Mobile is a medical device that can help clinicians in identifying the right patients for these potential new treatments."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

COG Market Data

Currency UK Pounds
Share Price 22.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 82.50
52 Week Low 22.00
Volume 4,359
Shares Issued 27.64m
Market Cap £6.08m
RiskGrade 356

COG Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
12.74% below the market average12.74% below the market average12.74% below the market average12.74% below the market average12.74% below the market average
44.44% above the sector average44.44% above the sector average44.44% above the sector average44.44% above the sector average44.44% above the sector average
Price Trend
95.28% below the market average95.28% below the market average95.28% below the market average95.28% below the market average95.28% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Income Not Available
Growth
37.67% below the market average37.67% below the market average37.67% below the market average37.67% below the market average37.67% below the market average
37.14% below the sector average37.14% below the sector average37.14% below the sector average37.14% below the sector average37.14% below the sector average

COG Dividends

No dividends found

Trades for 25-Feb-2020

Time Volume / Share Price
12:07 4,359 @ 22.65p

COG Key Personnel

Chair Michael Geoffrey Lewis
CFO Nick Walters
CEO Matthew Stork

Top of Page